Follow
Cancer Therapeutics
Cancer Therapeutics: Cancer is often treated by surgery, chemotherapy, radiation therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy), hormonal therapy, and synthetic lethality. The choice of therapy depends upon the stage of the disease, and the location and grade of the tumor, as well as the patient's general status. Many clinical trial cancer treatments are also under development.
OCT 16, 2013 | 2:00 PM
C.E. CREDITS
Non Small Cell Lung Cancer (NSCLC) is one of the most significant causes of cancer-related mortality worldwide. In about 6-7% of NSCLC, rearrangements involving the Anaplastic Lymphoma Kinase...
OCT 16, 2013 | 1:00 PM
C.E. CREDITS
Cancer cells have historically been classified by microscopic analysis of blood smears and tissue sections. Current technologies use molecular techniques to categorize and classify tumor cell...
OCT 16, 2013 | 12:00 PM
C.E. CREDITS
The eukaryotic translation initiation factor eIF4E is a potent oncogene estimated to be elevated in about 30% of human cancers including cancers of the breast, prostate, lung, colon as well a...
OCT 16, 2013 | 12:00 PM
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision making. Th...
OCT 16, 2013 | 11:00 AM
C.E. CREDITS
Cancer and diabetes are complex diseases that have proven difficult to treat in the clinics. Until recently, most efforts have focused on hitting individual therapeutic targets cleanly. Unfor...
OCT 16, 2013 | 11:00 AM
"SuperSelective" primers, by virtue of their unique design, enable only a few molecules of a mutant sequence to generate amplicons in conventional, real-time PCR assays without interference...
OCT 16, 2013 | 10:00 AM
C.E. CREDITS
The current paradigm of detecting established cancer (often too late) and treating routinely with cytotoxic drugs is beginning to change. Advanced technologies such as whole genome sequencin...
OCT 16, 2013 | 9:00 AM
C.E. CREDITS
It is now appreciated that breast cancer is not a single disease, but instead is a spectrum of tumor subtypes with distinct cellular origins, somatic changes and somewhat predictable clinical...
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
With the rapid rise in the number of therapeutic options for men with castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision-making, emphasizing the nee...
OCT 16, 2013 | 7:00 AM
C.E. CREDITS
The adjuvant therapy of choice for superficial bladder cancer is the intravesical instillation of live Mycobacterium bovis Bacillus Calmette-Guerin (BCG). In spite of the fact that this thera...
AUG 22, 2013 | 5:00 PM
C.E. CREDITS
Malignancies caused by so-called Type I chemical and biological carcinogens provide important opportunities studying early events in cancer development, providing essential information for de...
AUG 22, 2013 | 5:00 PM
As Chief of Scientific Intelligence at the John Wayne Cancer Institute, Dr. Hoon interacts with external academic, industry, and government agencies to develop innovative translational rese...
AUG 22, 2013 | 7:00 AM
Rheumatoid Arthritis (RA) is a heterogenous disease that affects 1.5% of the population. Similar to cancer, early detection coupled with an effective treatment strategy can significantly impr...
AUG 21, 2013 | 10:00 AM
C.E. CREDITS
Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retros...
SEP 12, 2012 | 9:00 AM
C.E. CREDITS
 The Project (PersonalGenomes.org) enables open observation and critique of a large cohort "test-driving" comprehensive participatory personalized medicine. This is the only fully open-access...
AUG 22, 2013 | 7:00 AM
Rheumatoid Arthritis (RA) is a heterogenous disease that affects 1.5% of the population. Similar to cancer, early detection coupled with an effective treatment strategy can significantly impr...
AUG 21, 2013 | 10:00 AM
C.E. CREDITS
Massively parallel sequencing technology has proven to enable the identification of driver genetic alterations in patients' tumors that may be suppressed by targeted therapies. Through retros...
SEP 12, 2012 | 9:00 AM
C.E. CREDITS
 The Project (PersonalGenomes.org) enables open observation and critique of a large cohort "test-driving" comprehensive participatory personalized medicine. This is the only fully open-access...